Table 1 Baseline characteristics of the study population
Characteristics | Total enrolled patients (n = 114) | SBRT + LEN group (n = 37) | LEN group (n = 77) | p value |
|---|---|---|---|---|
Gender, n (%) | ||||
Male | 100 (87.8%) | 32 (86.5%) | 68 (88.3%) | 1.000 |
Female | 14 (12.2%) | 5 (13.5%) | 9 (11.7%) | |
Age, years, n (%) | ||||
≥ 55 years | 60 (52.7%) | 21 (56.8%) | 39 (50.6%) | 0.541 |
< 55 years | 54 (47.3%) | 16 (43.2%) | 38 (49.4%) | |
HBV infection, n (%) | ||||
Yes | 107 (93.9%) | 34 (91.9%) | 73 (94.8%) | 0.680 |
No | 7 (6.1%) | 3 (8.1%) | 4 (5.2%) | |
Child–Pugh classification, n (%) | ||||
A | 96 (84.2%) | 31 (83.8%) | 65 (84.4%) | 0.931 |
B | 18 (15.8%) | 6 (16.2%%) | 12 (15.6%) | |
ECOG PS score, n (%) | ||||
0 | 49 (42.9%) | 17 (45.9%) | 32 (41.6%) | 0.658 |
1 | 65 (57.1%) | 20 (54.1%) | 45 (58.4%) | |
Number of tumors, n (%) | ||||
> 3 | 57 (50.0%) | 17 (45.9%) | 40 (51.9%) | 0.548 |
≤ 3 | 57 (50.0%) | 20 (54.1%) | 37 (48.1%) | |
Tumor size, n (%) | ||||
< 5 cm | 23 (20.2%) | 7 (18.9%) | 16 (20.8%) | 0.765 |
≥ 5 cm and < 10 cm | 53 (46.5%) | 19 (51.4%) | 34 (44.1%) | |
≥ 10 cm | 38 (33.3%) | 11 (29.7%) | 27 (35.1%) | |
PVTT, n (%) | ||||
VP1 | 7 (6.1%) | 1 (2.7%) | 6 (7.8%) | 0.707 |
VP2 | 44 (36.9%) | 16 (43.2%) | 28 (36.4%) | |
VP3 | 53 (50.9%) | 17 (45.9%) | 36 (46.8%) | |
VP4 | 10 (6.1%) | 3 (8.1%) | 7 (9.1%) | |
ALBI grade, n (%) | ||||
1 | 34 (29.8%) | 13 (35.1%) | 21 (27.3%) | 0.390 |
2 | 80 (70.2%) | 24 (64.9%) | 56 (72.7%) | |
AFP, n (%) | ||||
> 200 ng/mL | 55 (48.2%) | 18 (48.6%) | 37 (48.1%) | 0.952 |
≤ 200 ng/mL | 59 (51.8%) | 19 (51.4%) | 40 (51.9%) | |
PLT, n (%) | ||||
≥ 100 × 109/L | 86 (75.5%) | 28 (75.7%) | 58 (75.3%) | 0.967 |
< 100 × 109/L | 28 (24.5%) | 9 (24.3%) | 19 (24.7%) | |
WBC, n (%) | ||||
≥ 4 × 109/L | 78 (68.5%) | 25 (67.6%) | 53 (68.8%) | 0.892 |
< 4 × 109/L | 36 (31.5%) | 12 (32.4%) | 24 (31.2%) | |
Previous local treatment, n (%) | ||||
Absence | 102 (89.5%) | 34 (91.9%) | 68 (88.3%) | 0.797 |
Presence | ||||
TACE | 5 (4.4%) | 2 (5.4%) | 3 (3.9%) | |
Ablation | 3 (2.6%) | 1 (2.7%) | 2 (2.6%) | |
Argon–Helium cryosurgical | 4 (3.5%) | 0 (0%) | 4 (5.2%) | |